RaySearch Laboratories: Interim report January 1 - March 31, 2024
FIRST QUARTER (JANUARY -
- Oder intake
SEK 238.5 M (206.6) - Net sales
SEK 257.2 M (230.2) - Operating profit
SEK 45.8 M (23.7) - Profit after tax
SEK 36.7 M (17.6) - Earnings per share before/after dilution
SEK 1.07 (0.51) - Cash flow
SEK 87.9 M (84.5) - Order backlog
SEK 1,848.0 M (1,903.3) MSEK at the end of the period
SIGNIFICANT EVENTS DURING THE FIRTS QUARTER
- RayStation in more than 1,000 radiotherapy centers worldwide.
- The
Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis fromRaySearch . -
RaySearch acquires the product DrugLog from Pharmacolog. - World leading carbon ion center QST in
Chiba, Japan , selects RayStation.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
-
Raigmore Hospital inScotland selects RayCare. -
RaySearch and C-RAD signed collaboration agreement. - RayCare has been certified to be interoperable with Varian TrueBeam.
WEBCAST
CEO
Link to webcast:
You can also join the webcast by phone:
Sverige: +46 (0) 8 505 100 31
US: +1 (1) 631 570 56 13
The information contained in this interim report is such that
For more information, please contact:
Johan Löf, founder and CEO,
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/raysearch-laboratories/r/interim-report-january-1---march-31--2024,c3983281
The following files are available for download:
|
View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-interim-report-january-1--march-31-2024-302148757.html
SOURCE